Phase I Study of BI 853520, an Inhibitor of Focal Adhesion Kinase, in Patients with Advanced or Metastatic Nonhematologic Malignancies
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Phase I Study of BI 853520, an Inhibitor of Focal Adhesion Kinase, in Patients with Advanced or Metastatic Nonhematologic Malignancies
Authors
Keywords
-
Journal
Targeted Oncology
Volume 14, Issue 1, Pages 43-55
Publisher
Springer Nature
Online
2019-02-11
DOI
10.1007/s11523-018-00617-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase I Study of the Focal Adhesion Kinase Inhibitor BI 853520 in Japanese and Taiwanese Patients with Advanced or Metastatic Solid Tumors
- (2019) Toshihiko Doi et al. Targeted Oncology
- Efficacy of the highly selective focal adhesion kinase inhibitor BI 853520 in adenocarcinoma xenograft models is linked to a mesenchymal tumor phenotype
- (2018) Ulrich A. Hirt et al. Oncogenesis
- Phase I study of defactinib combined with pembrolizumab and gemcitabine in patients with advanced cancer.
- (2018) Andrea Wang-Gillam et al. JOURNAL OF CLINICAL ONCOLOGY
- The FAK inhibitor BI 853520 exerts anti-tumor effects in breast cancer
- (2018) Stefanie Tiede et al. Oncogenesis
- A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors
- (2016) J. C. Soria et al. ANNALS OF ONCOLOGY
- A first-in-Asian phase 1 study to evaluate safety, pharmacokinetics and clinical activity of VS-6063, a focal adhesion kinase (FAK) inhibitor in Japanese patients with advanced solid tumors
- (2016) Toshio Shimizu et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Molecular Pathways: Endothelial Cell FAK--A Target for Cancer Treatment
- (2016) M. Roy-Luzarraga et al. CLINICAL CANCER RESEARCH
- CT-707, a Novel FAK Inhibitor, Synergizes with Cabozantinib to Suppress Hepatocellular Carcinoma by Blocking Cabozantinib-Induced FAK Activation
- (2016) Dan-Dan Wang et al. MOLECULAR CANCER THERAPEUTICS
- Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy
- (2016) Hong Jiang et al. NATURE MEDICINE
- Nuclear FAK Controls Chemokine Transcription, Tregs, and Evasion of Anti-tumor Immunity
- (2015) Alan Serrels et al. CELL
- Anti-metastatic action of FAK inhibitor OXA-11 in combination with VEGFR-2 signaling blockade in pancreatic neuroendocrine tumors
- (2015) Ingrid Moen et al. CLINICAL & EXPERIMENTAL METASTASIS
- A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors
- (2015) Suzanne F. Jones et al. INVESTIGATIONAL NEW DRUGS
- FAK signaling in human cancer as a target for therapeutics
- (2015) Brian Y. Lee et al. PHARMACOLOGY & THERAPEUTICS
- Down-Regulation of Integrin β1 and Focal Adhesion Kinase in Renal Glomeruli under Various Hemodynamic Conditions
- (2014) Xiaoli Yuan et al. PLoS One
- The role of FAK in tumor metabolism and therapy
- (2013) Jianliang Zhang et al. PHARMACOLOGY & THERAPEUTICS
- 387 The Focal Adhesion Kinase Inhibitor GSK2256098: a Potent and Selective Inhibitor for the Treatment of Cancer
- (2012) K.R. Auger et al. EUROPEAN JOURNAL OF CANCER
- Safety, Pharmacokinetic, and Pharmacodynamic Phase I Dose-Escalation Trial of PF-00562271, an Inhibitor of Focal Adhesion Kinase, in Advanced Solid Tumors
- (2012) Jeffrey R. Infante et al. JOURNAL OF CLINICAL ONCOLOGY
- Abstract A249: BI 853520, a potent and highly selective inhibitor of protein tyrosine kinase 2 (focal adhesion kinase), shows efficacy in multiple xenograft models of human cancer.
- (2012) U. A. Hirt et al. MOLECULAR CANCER THERAPEUTICS
- Inhibition of Podocyte FAK Protects against Proteinuria and Foot Process Effacement
- (2010) H. Ma et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- EMT, the cytoskeleton, and cancer cell invasion
- (2009) Mahmut Yilmaz et al. CANCER AND METASTASIS REVIEWS
- Signal transduction by focal adhesion kinase in cancer
- (2009) Jihe Zhao et al. CANCER AND METASTASIS REVIEWS
- Dual focal adhesion kinase/Pyk2 inhibitor has positive effects on bone tumors
- (2008) Cedo M. Bagi et al. CANCER
- Antitumor Activity and Pharmacology of a Selective Focal Adhesion Kinase Inhibitor, PF-562,271
- (2008) W. G. Roberts et al. CANCER RESEARCH
- Focal Adhesion Kinase: Targeting Adhesion Signaling Pathways for Therapeutic Intervention
- (2008) J. T. Parsons et al. CLINICAL CANCER RESEARCH
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started